CA3232623A1 - Methods of treating myelodysplastic syndromes with decitabine and cedazuridine - Google Patents

Methods of treating myelodysplastic syndromes with decitabine and cedazuridine Download PDF

Info

Publication number
CA3232623A1
CA3232623A1 CA3232623A CA3232623A CA3232623A1 CA 3232623 A1 CA3232623 A1 CA 3232623A1 CA 3232623 A CA3232623 A CA 3232623A CA 3232623 A CA3232623 A CA 3232623A CA 3232623 A1 CA3232623 A1 CA 3232623A1
Authority
CA
Canada
Prior art keywords
effective amount
decitabine
cedazuridine
survival
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3232623A
Other languages
English (en)
French (fr)
Inventor
Harold Keer
Mohammad Azab
Yong Hao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CA3232623A1 publication Critical patent/CA3232623A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3232623A 2021-09-21 2022-09-21 Methods of treating myelodysplastic syndromes with decitabine and cedazuridine Pending CA3232623A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163246547P 2021-09-21 2021-09-21
US63/246,547 2021-09-21
PCT/US2022/076757 WO2023049731A2 (en) 2021-09-21 2022-09-21 Methods of treating myelodysplastic syndromes with decitabine and cedazuridine

Publications (1)

Publication Number Publication Date
CA3232623A1 true CA3232623A1 (en) 2023-03-30

Family

ID=85721229

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3232623A Pending CA3232623A1 (en) 2021-09-21 2022-09-21 Methods of treating myelodysplastic syndromes with decitabine and cedazuridine

Country Status (10)

Country Link
US (1) US20250000888A1 (cg-RX-API-DMAC7.html)
EP (1) EP4404940A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024531799A (cg-RX-API-DMAC7.html)
KR (1) KR20240064656A (cg-RX-API-DMAC7.html)
CN (1) CN118201622A (cg-RX-API-DMAC7.html)
AU (1) AU2022348907B2 (cg-RX-API-DMAC7.html)
CA (1) CA3232623A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024003537A (cg-RX-API-DMAC7.html)
TW (1) TW202327625A (cg-RX-API-DMAC7.html)
WO (1) WO2023049731A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023548303A (ja) 2020-10-29 2023-11-16 大塚製薬株式会社 癌を処置する為の医薬組成物及びその使用方法
AU2024265282A1 (en) * 2023-05-02 2025-12-18 Taiho Pharmaceutical Co., Ltd. Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2708264C (en) * 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
US10683552B2 (en) * 2014-11-25 2020-06-16 Presidents And Fellows Of Harvard College Clonal haematopoiesis
US11224610B2 (en) * 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
WO2021113688A1 (en) * 2019-12-05 2021-06-10 Sumitomo Dainippon Pharma Oncology, Inc. Combination therapies for treatment of myelodysplastic syndrome
EP4090335A1 (en) * 2020-01-17 2022-11-23 Novartis AG Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
LT4069254T (lt) * 2020-02-25 2024-10-10 Otsuka Pharmaceutical Co., Ltd. Kietos geriamosios vaisto formos, apimančios decitabiną ir cedazuridiną

Also Published As

Publication number Publication date
JP2024531799A (ja) 2024-08-29
US20250000888A1 (en) 2025-01-02
AU2022348907B2 (en) 2026-07-16
WO2023049731A2 (en) 2023-03-30
AU2022348907A1 (en) 2024-04-11
WO2023049731A3 (en) 2023-05-04
TW202327625A (zh) 2023-07-16
CN118201622A (zh) 2024-06-14
EP4404940A4 (en) 2025-07-30
MX2024003537A (es) 2024-05-03
EP4404940A2 (en) 2024-07-31
KR20240064656A (ko) 2024-05-13

Similar Documents

Publication Publication Date Title
TWI729492B (zh) 使用包含微脂體伊立替康(irinotecan)的組合療法治療胰臟癌的方法
US20220249528A1 (en) Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
US9532984B2 (en) Therapeutic combination for cancer treatment
RU2739992C2 (ru) Композиции апилимода и способы их применения в лечении колоректального рака
US20250000888A1 (en) Methods of treating myelodysplastic syndromes with decitabine and cedazuridine
TWI912283B (zh) 地西他濱及西屈嘧啶(cedazuridine)組合之固體口服劑型
US11938143B2 (en) Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
WO2023201338A1 (en) Combination therapy comprising a mat2a inhibitor and a parp inhibitor
CN110392573A (zh) 用于在血液肿瘤中的HDM2-p53相互作用抑制剂的剂量和方案
US20220168329A1 (en) Combinatorial drug treatment of cancer
JP2026083415A (ja) 癌を処置する為の医薬組成物及びその使用方法
IL292882A (en) Dosage of Bruton's tyrosine kinase inhibitor
HK40105549A (en) Methods of treating myelodysplastic syndromes with decitabine and cedazuridine
WO2024118943A2 (en) Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor
JP2024513260A (ja) 骨髄癌処置のためのlsd1阻害剤の組み合わせ
US20110301102A1 (en) Compositions and methods for treating myelodysplastic syndrome
WO2021211890A1 (en) Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
Leong et al. Bendamustine (Treanda) for chronic lymphocytic leukemia: a brief overview
WO2023177894A1 (en) Combination therapy comprising a mat2a inhibitor and an antimetabolite agent
US11052101B2 (en) Methods for treating cancer using purine analogs by depleting intracellular ATP
HK40112908A (en) Treatment of severe and uncomplicated malaria
NZ788615B2 (en) Dosing of a bruton's tyrosine kinase inhibitor
WO2013019222A1 (en) Compositions and methods for treating myelodysplastic syndrome
HK1162149A (en) Compositions for use in treating myelodysplastic syndrome

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240917

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240917

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240917

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250822

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250822

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20251128

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251128

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251201

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260702

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260702

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260702

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260707

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260728

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260728

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260728

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260728

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260728

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260729

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260806

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260806